Wave Life Sciences (NASDAQ:WVE) has announced encouraging results from its Phase 1b/2a SELECT-HD clinical trial for WVE-003, a candidate treatment for Huntington’s disease (HD).
The study demonstrated a statistically significant reduction in mutant huntingtin (mHTT) protein levels by 46% compared to placebo, while preserving the wild-type huntingtin (wtHTT) protein.
Anne-Marie Li-Kwai-Cheung, Chief Development Officer at Wave Life Sciences, expressed pride in the results, stating, “We are very proud to have demonstrated mHTT lowering of 46%, with preservation of wtHTT."
The company plans to engage regulators to discuss a potential accelerated approval for WVE-003.